Related content

Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer

By                          

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 405-410

Spandidos Publications

Access to resources Recommend Favorite

Phase II study of erlotinib for previously treated patients with EGFR wildtype nonsmallcell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 991-996

Spandidos Publications

Access to resources Recommend Favorite

Efficacy of tyrosine kinase inhibitors in nonsmallcell lung cancer patients undergoing dose reduction and those with a low body surface area

By                    

Molecular and Clinical Oncology, Vol. 2, Iss. 4, 2014-01 ,pp. : 604-608

Spandidos Publications

Access to resources Recommend Favorite

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for nonsmallcell lung cancer (Review)

By              

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 8-12

Spandidos Publications

Access to resources Recommend Favorite

Cyclooxygenase-2 Inhibitors: A Painful Lesson

By  

Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol. 6, Iss. 2, 2006-06 ,pp. : 83-98

Bentham Science Publishers

Access to resources Recommend Favorite